High-purity, plasma-derived, pasteurized Factor VIII concentrates in the treatment of patients with haemophilia A: update of a long-term pharmacovigilance study

被引：0
|
作者：
Klamroth, Robert [1 ]
Holzhauer, Susanne [2 ]
Heller, Christine [3 ]
Sommerer, Patrick [4 ]
Kurnik, Karin [5 ]
机构：
[1] Vivantes Klinikum Friedrichshain, Berlin, Germany
[2] Univ Hosp Charite, Berlin, Germany
[3] Goethe Univ Frankfurt, Comprehens Care Ctr Thrombosis & Haemostasis, D-60054 Frankfurt, Germany
[4] CSL Behring GmbH, Marburg, Germany
[5] Univ Hosp Munich, Dr v Haunersches Childrens Hosp, Munich, Germany
来源：
HAEMOPHILIA | 2014年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：24 / 24
页数：1
相关论文
共 50 条
  • [41] One plasma-derived factor VIII concentrate in patients with severe haemophilia A undergoing major orthopedic surgical procedures
    Klamroth, R.
    Gottstein, S.
    Essers, E.
    Heinrichs, C.
    HAEMOPHILIA, 2008, 14 : 12 - 12
  • [42] BERIATE® P in the treatment of patients with hemophilia A: update of a long-term pharmacovigilance
    Klamroth, R.
    Zimmermann, R.
    Kurnik, K.
    Holzhauer, S.
    Geist, M.
    HAEMOPHILIA, 2010, 16 : 36 - 36
  • [43] Pharmacokinetics of a high-purity plasma-derived factor X concentrate in subjects with moderate or severe hereditary factor X deficiency
    Austin, S. K.
    Brindley, C.
    Kavakli, K.
    Norton, M.
    Shapiro, A.
    HAEMOPHILIA, 2016, 22 (03) : 426 - 432
  • [44] SUCCESSFUL TREATMENT OF CONGENITAL TTP WITH KOATE-DVI, AN INTERMEDIATE PURITY PLASMA-DERIVED FACTOR VIII CONCENTRATE
    Jacobson, Richard
    Nguyen-Vermillion, Annie
    Kent, Paul
    Valentino, Leonard
    PEDIATRIC BLOOD & CANCER, 2015, 62 : 62 - 63
  • [45] Long-term outcome of haemophilia A patients after successful immune tolerance induction therapy using a single plasma-derived FVIII/VWF product: the long-term ITI study
    Jimenez-Yuste, V.
    Oldenburg, J.
    Rangarajan, S.
    Peiro-Jordan, R.
    Santagostino, E.
    HAEMOPHILIA, 2016, 22 (06) : 859 - 865
  • [46] A qualitative and quantitative analysis of von Willebrand factor contained in a very high-purity plasma-derived FVIII concentrate
    Samor, B.
    Michalski, C.
    Brandin, M-P.
    Andre, M-H.
    Chtourou, S.
    Tellier, Z.
    VOX SANGUINIS, 2012, 103 (01) : 35 - 41
  • [47] Long-term treatment course of a patient with mild haemophilia A who developed a high titre factor VIII inhibitor
    Iioka, F.
    Shimomura, D.
    Nakamura, F.
    Ohno, H.
    Yada, K.
    Nogami, K.
    Shima, M.
    HAEMOPHILIA, 2014, 20 (06) : E402 - E404
  • [48] Interferon-gamma secretion defects in haemophilia A patients receiving highly purified plasma-derived or recombinant factor VIII
    NewtonNash, DK
    Tollerud, D
    Guevarra, L
    Gill, JC
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 95 (03) : 554 - 560
  • [49] INCIDENCE OF FACTOR-VIII INHIBITOR DEVELOPMENT IN HEMOPHILIA-A PATIENTS TREATED WITH LESS PURE PLASMA-DERIVED CONCENTRATES
    DEBIASI, R
    ROCINO, A
    PAPA, ML
    SALERNO, E
    MASTRULLO, L
    DEBLASI, D
    THROMBOSIS AND HAEMOSTASIS, 1994, 71 (05) : 544 - 547
  • [50] Beriate® P in the treatment of patients with hemophilia A:: third update of a long-term pharmacovigilance
    Klamroth, R.
    Zimmermann, R.
    Von Stackelberg, A.
    Zacharias, C.
    Fremann, S.
    Kurnik, K.
    HAEMOPHILIA, 2008, 14 : 14 - 14
12345